Product Description
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Innervate Radiopharmaceuticals
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Neuroblastoma
Phase 2: Coronary Disease|Heart Failure|Heart Failure, Chronic|Heart Failure, Systolic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06965621 |
IRP101-221 | P2 |
Recruiting |
Heart Failure |
2026-10-30 |
2% |
2026-07-02 |
Primary Endpoints|Start Date |
NCT04535193 |
IRP101-121 | P2 |
Active, not recruiting |
Coronary Disease|Heart Failure, Chronic|Heart Failure, Systolic |
2025-03-07 |
3% |
2026-07-03 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT04724369 |
IRP101-301 | P3 |
Active, not recruiting |
Neuroblastoma |
2026-07-30 |
16% |
2026-04-04 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|